Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2022-08-03 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Aptar Pharma Pays PXS Us$5m to Acquire Orbital Technology 3 pages 167.6KB
Capital/Financing Update Classification · 95% confidence The document is a media release dated 4 August 2022 announcing that Aptar Pharma has exercised an option and paid Pharmaxis to acquire the Orbital technology, a drug delivery inhaler. The content focuses on a business transaction involving licensing and acquisition of technology rights, describing the strategic rationale and background of both companies. There are no financial statements, quarterly or annual results, or regulatory filings such as 10-K or interim reports. The document is not a call transcript, audit report, or governance information. It is a corporate announcement about a capital transaction related to technology acquisition and licensing. This fits best under Capital/Financing Update (CAP) as it relates to a financing and capital transaction update involving payments and acquisition of rights. The document length is 8083 characters, which is substantive and not a mere announcement of a report publication. Therefore, the classification is CAP with high confidence.
2022-08-03 English
Quarterly Appendix 4C Cash Flow Report 5 pages 206.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is a quarterly cash flow report for Pharmaxis Ltd for the quarter ended 30 June 2022. It contains detailed consolidated cash flow statements including operating, investing, and financing activities, as well as reconciliations and commentary on funding and cash availability. The document references compliance with ASX Listing Rule 4.7B, which mandates quarterly cash flow reporting for listed entities. The length is substantial (15,000 characters) and contains actual financial data and analysis for a quarter, not just an announcement or certification. This fits the definition of an Interim / Quarterly Report (IR) as it is a comprehensive financial report for a period shorter than a full fiscal year with substantive financial data and analysis. Q4 2022
2022-07-28 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 480.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – June 2022' and contains detailed information about clinical trials, drug development programs, sales impact, and operational updates for the quarter ending June 2022. It includes substantive financial and operational data relevant to a quarterly period, not just an announcement or summary. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content focuses on quarterly progress and pipeline updates, consistent with an Interim / Quarterly Report. There is no indication that this is an Annual Report, Earnings Release, or other specific filing type. Therefore, the document fits best as an Interim / Quarterly Report (IR). Q4 2022
2022-07-28 English
Investor presentation 20 pages 1.9MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and dated 29 July 2022. It contains detailed information about the company's clinical pipeline, drug development programs, market opportunities, trial designs, financial information, and shareholder data. The content is structured as a presentation aimed at investors, focusing on strategy, product pipeline, clinical trials, and market potential rather than providing formal financial statements or regulatory disclosures. There is no indication that this is an official annual or quarterly report, audit report, or earnings release. The length is substantial (15,000 characters), consistent with a detailed presentation. Therefore, the document fits the category of an Investor Presentation (IP).
2022-07-28 English
Investor presentation for quarterly shareholder update 7 pages 910.9KB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation | 29 July 2022' and contains detailed information about the company's clinical pipeline, financial position, market strategy, and recent updates. It includes forward-looking statements, clinical trial statuses, financial metrics like share price and market cap, and management contacts. There are no full financial statements or comprehensive fiscal year or quarter reports, but rather a presentation aimed at investors summarizing strategy, progress, and outlook. This matches the definition of an Investor Presentation (IP). The document length is 7751 characters, which is consistent with a detailed presentation rather than a brief announcement or a full annual/interim report.
2022-07-28 English
Pharmaxis Quarterly Shareholder Update and Investor Briefing 2 pages 126.5KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 26 July 2022 announcing a quarterly shareholder update and investor briefing scheduled for 29 July 2022. It invites investors and analysts to participate in a virtual briefing with a presentation and Q&A session. The document does not contain actual financial statements or substantive financial data but rather serves as an announcement of an upcoming event where such information might be discussed. The length is under 5,000 characters and it primarily functions as a notice for the investor briefing and shareholder update. Therefore, it is not the quarterly report itself but an announcement related to it. According to the classification rules, such announcements are best classified as Regulatory Filings (RNS) since they do not fit the definition of an Interim/Quarterly Report (IR) or an Investor Presentation (IP) because the actual report or presentation is not included, only the announcement of the event.
2022-07-25 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.